Cargando…

Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability

Circulating tumor cells (CTCs) provide an accessible tool for investigating tumor heterogeneity and cell populations with metastatic potential. Although an in-depth molecular investigation is limited by the extremely low CTC count in circulation, significant progress has been made recently in single...

Descripción completa

Detalles Bibliográficos
Autores principales: Tayoun, Tala, Oulhen, Marianne, Aberlenc, Agathe, Farace, Françoise, Pawlikowska, Patrycja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915006/
https://www.ncbi.nlm.nih.gov/pubmed/33562741
http://dx.doi.org/10.3390/cells10020337
_version_ 1783657136747708416
author Tayoun, Tala
Oulhen, Marianne
Aberlenc, Agathe
Farace, Françoise
Pawlikowska, Patrycja
author_facet Tayoun, Tala
Oulhen, Marianne
Aberlenc, Agathe
Farace, Françoise
Pawlikowska, Patrycja
author_sort Tayoun, Tala
collection PubMed
description Circulating tumor cells (CTCs) provide an accessible tool for investigating tumor heterogeneity and cell populations with metastatic potential. Although an in-depth molecular investigation is limited by the extremely low CTC count in circulation, significant progress has been made recently in single-cell analytical processes. Indeed, CTC monitoring through molecular and functional characterization may provide an understanding of genomic instability (GI) molecular mechanisms, which contribute to tumor evolution and emergence of resistant clones. In this review, we discuss the sources and consequences of GI seen through single-cell analysis of CTCs in different types of tumors. We present a detailed overview of chromosomal instability (CIN) in CTCs assessed by fluorescence in situ hybridization (FISH), and we reveal utility of CTC single-cell sequencing in identifying copy number alterations (CNA) oncogenic drivers. We highlight the role of CIN in CTC-driven metastatic progression and acquired resistance, and we comment on the technical obstacles and challenges encountered during single CTC analysis. We focus on the DNA damage response and depict DNA-repair-related dynamic biomarkers reported to date in CTCs and their role in predicting response to genotoxic treatment. In summary, the suggested relationship between genomic aberrations in CTCs and prognosis strongly supports the potential utility of GI monitoring in CTCs in clinical risk assessment and therapeutic choice.
format Online
Article
Text
id pubmed-7915006
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79150062021-03-01 Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability Tayoun, Tala Oulhen, Marianne Aberlenc, Agathe Farace, Françoise Pawlikowska, Patrycja Cells Review Circulating tumor cells (CTCs) provide an accessible tool for investigating tumor heterogeneity and cell populations with metastatic potential. Although an in-depth molecular investigation is limited by the extremely low CTC count in circulation, significant progress has been made recently in single-cell analytical processes. Indeed, CTC monitoring through molecular and functional characterization may provide an understanding of genomic instability (GI) molecular mechanisms, which contribute to tumor evolution and emergence of resistant clones. In this review, we discuss the sources and consequences of GI seen through single-cell analysis of CTCs in different types of tumors. We present a detailed overview of chromosomal instability (CIN) in CTCs assessed by fluorescence in situ hybridization (FISH), and we reveal utility of CTC single-cell sequencing in identifying copy number alterations (CNA) oncogenic drivers. We highlight the role of CIN in CTC-driven metastatic progression and acquired resistance, and we comment on the technical obstacles and challenges encountered during single CTC analysis. We focus on the DNA damage response and depict DNA-repair-related dynamic biomarkers reported to date in CTCs and their role in predicting response to genotoxic treatment. In summary, the suggested relationship between genomic aberrations in CTCs and prognosis strongly supports the potential utility of GI monitoring in CTCs in clinical risk assessment and therapeutic choice. MDPI 2021-02-05 /pmc/articles/PMC7915006/ /pubmed/33562741 http://dx.doi.org/10.3390/cells10020337 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tayoun, Tala
Oulhen, Marianne
Aberlenc, Agathe
Farace, Françoise
Pawlikowska, Patrycja
Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability
title Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability
title_full Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability
title_fullStr Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability
title_full_unstemmed Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability
title_short Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability
title_sort tumor evolution and therapeutic choice seen through a prism of circulating tumor cell genomic instability
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915006/
https://www.ncbi.nlm.nih.gov/pubmed/33562741
http://dx.doi.org/10.3390/cells10020337
work_keys_str_mv AT tayountala tumorevolutionandtherapeuticchoiceseenthroughaprismofcirculatingtumorcellgenomicinstability
AT oulhenmarianne tumorevolutionandtherapeuticchoiceseenthroughaprismofcirculatingtumorcellgenomicinstability
AT aberlencagathe tumorevolutionandtherapeuticchoiceseenthroughaprismofcirculatingtumorcellgenomicinstability
AT faracefrancoise tumorevolutionandtherapeuticchoiceseenthroughaprismofcirculatingtumorcellgenomicinstability
AT pawlikowskapatrycja tumorevolutionandtherapeuticchoiceseenthroughaprismofcirculatingtumorcellgenomicinstability